Immune checkpoint inhibitors and kinase inhibitors have improved prognosis of malignant melanoma (MM) patients. However, these therapies cannot completely overcome the metastasis of MM. Thus, development of new therapy against metastasis should be required. A first step towards this goal, the aim of this study, is to establish a model of pulmonary metastasis from primary cutaneous MM and a monitoring system. B16-F10, a murine melanoma cell line, was subcutaneously injected into the pinna of mice. The pinna was excised when the lesion was detected.
| BACKGROUND
Malignant melanoma (MM), one of the most life-threatening forms of cancer, has been on the rise. Primary MM is curable by surgical excision at the early stage and has a five-year survival rate in 97% of patients.
On the other hand, management of patients with metastatic MM is difficult due to the high potential for metastasis; the one-year survival rate for MM is 33-62% at stage IV. [1] Recently, new treatment options, including immune checkpoint inhibitors and kinase inhibitors, have been approved for progressive MM. Immune checkpoint inhibitors, combination of nivolumab and ipilimumab, achieved for 2 years overall survival about 65% of patients. [2] Approximately 45% of melanoma patients harbouring an activating BRAF V600E mutation respond to kinase inhibitors, vemurafenib or dabrafenib. These agents show significant increase in overall and progression-free survival compared with dacarbazine. [3] Although these therapies significantly improve prognosis of MM patient, substantial number of the patients died of distant metastases. Therefore, development of a new treatment or combination of current therapies to target metastasis is required. A first step towards this goal is to establish a murine MM metastatic model.
| QUESTIONS ADDRESSED
The aim of this study was to establish a model of pulmonary metastasis from primary cutaneous MM and a monitoring system capable of periodically detecting metastatic lesions in the lungs without dissection.
| EXPERIMENTAL DESIGN
B16-F10, a murine melanoma cell line, was subcutaneously injected (1×10 6 cells/mouse) into the pinna of mature female C57BL/6 mice.
The melanoma cells formed a nodule on the pinna, and when the lesion was around 8 mm in diameter, the pinna was excised. The end point was set at 9 weeks from injection ( samples were able to be visualized by MRI, [4] and were performed in this study when the primary lesion on the pinna was excised, then again at 4 weeks after resection.
| RESULTS
The pinna, the site of the melanoma cell injection, was excised within 13 days postinjection (average; 9.6 days; Table 1 ). No pulmonary metastatic nodules were visible by MRI at the surgical excision of the primary lesion on the pinna ( Figure 1A ). However, a metastatic nodule with medium signal intensity on T2-weighted imaging was detected 4 weeks after resection of the pinna ( Figure 1B ). 
| DISCUSSION
Several metastatic models of murine melanoma have been reported.
In these reports, murine melanoma cells were injected intravenously into the tail vein, or the intraperitoneal or retroperitoneal space, [5, 6] and the pulmonary metastatic lesions were analysed.
Metastasis comprises several steps, including vascular invasion, spreading to blood vessels or lymphatic vessels, infiltration into extravascular spaces and proliferation of tumor cells in the target organ. Thus, the process of vascular invasion by tumor cells cannot be explored using the intravenous or peritoneal injection models.
On the other hand, pulmonary metastatic lesions rarely developed via an intradermal or subcutaneous injection of melanoma cells into the footpad, pinna or tail. [7, 8] Here, we have established a new in vivo metastatic model of MM. Intradermally injected melanoma cells efficiently metastasize to the lung in our model. However, we employed B16F10 cell, which was a high metastatic mouse melanoma cell. Next, we plan to utilize human melanoma cells for our model. Previous report showed the difficulty in development of metastasis model by human melanoma cells. [9] Thus, immunodefi- 
| CONCLUSIONS
We established a novel murine model of the high pulmonary metastasis of B16-F10 melanoma cells, which can serve as an excellent tool for investigating the mechanism of pulmonary metastasis of melanoma. The MRI was useful for time series observations of the growth of the metastatic lesions. Further, the "pinna model" reported here allowed us to develop a novel antimetastatic drug, and to elucidate the mechanism underlying metastasis. 
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